Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world secukinumab retention and effectiveness in psoriasis in Japan
jRCT1080225042Completed
- Sponsor
- Novartis
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of secukinumab in plaque psoriasis and psoriatic arthritis (PsA), sponsored by Novartis. Primary endpoint: Secukinumab drug retention at Week 52. Started Jan 2020; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on jRCT1080225042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080225042.